ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment for metastatic non-small cell lung cancer

•The phase III ARCTIC study evaluated durvalumab ± tremelimumab versus SoC in heavily pretreated patients with metastatic NSCLC•Durvalumab monotherapy showed clinically meaningful improvements in OS and PFS versus SoC in patients with PD-L1 TC ≥25%•Durvalumab + tremelimumab showed numerical improvements in OS and PFS versus SoC in patients with PD-L1 TC <25%•Safety profiles of durvalumab and tremelimumab were consistent with previous studies